Review : Factor V Arg506 → Gln mutation in patients with antiphospholipid antibodies

Abstract

Antiphospholipid antibodies (APA) have thought to be implicated in the pathogenesis of both arterial and venous thrombosis. Because of heterogeneity of APA, direct evidence of their involvement in a thrombotic event is not yet available. Development of thrombosis in the antiphospholipid antibody syndrome (APS) may occur because of the presence of addi tional risk factors. Here we have analysed 60 patients with APA for the presence of the Arg⁵⁰⁶ → Gln mutation in factor V. Among them 26 suffered from deep venous thrombosis, 13 from arterial thrombosis and 21 had no history of arterial or venous thrombosis. In the first group four patients were found to be heterozygous and one homozygous for the factor V Arg⁵⁰⁶ → Gln mutation. None of the patients with the factor V mutation was found in the second and third group. The incidence of factor V mutation was significantly elevated in the group of patients with venous thrombosis. These data suggest that in patients with anti phospholipid antibodies the factor V Arg⁵⁰⁶ → Gln mutation may play a major role in the occurrence of venous thrombosis.

Keywords

APA factor V arterial thrombosis venous thrombosis

Get full access to this article

View all access options for this article.

References

Roubey Ras. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulant and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.

Triplett DA Antiphospholipid-protein antibodies: laboratory detection and clinical relevance . Thromb Res 1995; 78: 1-31.

de Groot PG , Derksen Rhwm. Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 1994; 3: 229-233.

Dahlbäck B. New molecular insights into the genetics of thrombophilia. Thromb Haemost 1995; 74: 139-148.

Davies KA , Ireland H. , Athanassiou P. et al. Factor V Leiden mutation and venous thrombosis. Lancet 1995; 345: 132-133.

Dizon-Twonson D. , Hutchinson C. , Silver R. et al. The factor V mutation which predisposes to thrombosis is not common in patients with antiphospholipid antibodies syndrome . Thromb Haemost 1995; 74: 1029-1031.

Bokarewa MI , Bremme K. , Falk G. et al. Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 3: 193-200.

Exner T. , Triplett DA , Taberner D. , Machin SJ Guidelines for testing and revised criteria for lupus anticoagulant. SSC Subcommittee for the standardization of lupus anticoagulant. Thromb Haemost 1991; 65: 320-332.

Triplett DA Laboratory diagnosis of lupus anticoagulants. Seminars in Thromb Haemost 1990; 16: 182-192.

10.

Harris EN , Pierangeli S. , Birch D. Anticardiolipin wet workshop report: fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 46: 1-6.

11.

Voorberg J. , Roelse J. , Koopman R. et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536.

12.

Bertina RM , Koeleman Bpc , Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.

13.

Hasselaar P. , Derksen Rhwm , Oosting JD et al. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by endothelial cells. Thromb Haemost 1989; 62: 654-660.

14.

Derksen Rhwm , Hasselaar P. , Blokzijl L. et al. Coagulation screen is more specific than anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheumatol Dis 1988; 47: 364-371.